دورية أكاديمية
Teprotumumab-related Cutaneous Hypersensitivity Reactions.
| العنوان: | Teprotumumab-related Cutaneous Hypersensitivity Reactions. |
|---|---|
| المؤلفون: | Dallalzadeh LO; Division of Oculofacial Plastic and Reconstructive Surgery, Viterbi Family Department of Ophthalmology, Shiley Eye Institute, UC San Diego, La Jolla, CA, U.S.A., Ting M; Division of Oculofacial Plastic and Reconstructive Surgery, Viterbi Family Department of Ophthalmology, Shiley Eye Institute, UC San Diego, La Jolla, CA, U.S.A., Topilow N; Division of Oculofacial Plastic and Reconstructive Surgery, Viterbi Family Department of Ophthalmology, Shiley Eye Institute, UC San Diego, La Jolla, CA, U.S.A., Robbins SL; Division of Pediatric Ophthalmology and Adult Strabismus, Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, CA, U.S.A., Liu CY; Division of Oculofacial Plastic and Reconstructive Surgery, Viterbi Family Department of Ophthalmology, Shiley Eye Institute, UC San Diego, La Jolla, CA, U.S.A., Burkat CN; Division of Ophthalmic Facial Plastic Surgery, Department of Ophthalmology and Visual Sciences, University of Wisconsin Madison, Madison, WI, U.S.A., Korn BS; Division of Oculofacial Plastic and Reconstructive Surgery, Viterbi Family Department of Ophthalmology, Shiley Eye Institute, UC San Diego, La Jolla, CA, U.S.A.; Division of Plastic and Reconstructive Surgery, Department of Surgery, UC San Diego, La Jolla, CA, U.S.A., Kikkawa DO; Division of Oculofacial Plastic and Reconstructive Surgery, Viterbi Family Department of Ophthalmology, Shiley Eye Institute, UC San Diego, La Jolla, CA, U.S.A.; Division of Plastic and Reconstructive Surgery, Department of Surgery, UC San Diego, La Jolla, CA, U.S.A. |
| المصدر: | Ophthalmic plastic and reconstructive surgery [Ophthalmic Plast Reconstr Surg] 2023 Nov-Dec 01; Vol. 39 (6), pp. e208-e210. Date of Electronic Publication: 2023 Sep 01. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins for the American Society of Ophthalmic Plastic and Reconstructive Surgery Country of Publication: United States NLM ID: 8508431 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-2677 (Electronic) Linking ISSN: 07409303 NLM ISO Abbreviation: Ophthalmic Plast Reconstr Surg Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 199 - : Hagerstown, MD : Lippincott Williams & Wilkins for the American Society of Ophthalmic Plastic and Reconstructive Surgery Original Publication: [New York, NY : Raven Press Publishers], c1985- |
| مواضيع طبية MeSH: | Antibodies, Monoclonal, Humanized*/adverse effects , Graves Ophthalmopathy*, Humans ; Antibodies, Monoclonal |
| مستخلص: | The authors report 4 cases of cutaneous hypersensitivity reactions developing in the course of teprotumumab treatment for thyroid eye disease. The onset of the cutaneous hypersensitivity reaction was also observed during the treatment course in all cases, between the second and fifth infusions. Teprotumumab-related cutaneous reactions suggest a possible immunogenic component of the monoclonal antibody and highlight the importance of close monitoring during treatment. (Copyright © 2023 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.) |
| References: | Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376:1748–1761. Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382:341–352. Ozzello DJ, Kikkawa DO, Korn BS. Early experience with teprotumumab for chronic thyroid eye disease. Am J Ophthalmol Case Rep. 2020;19:100744. Ozzello DJ, Dallalzadeh LO, Liu CY. Teprotumumab for chronic thyroid eye disease. Orbit. 2022;41:539–546. Ugradar S, Kang J, Kossler AL, et al. Teprotumumab for the treatment of chronic thyroid eye disease. Eye (Lond). 2022;36:1553–1559. Diniz SB, Cohen LM, Roelofs KA, et al. Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population. Ophthalmic Plast Reconstr Surg. 2021;37:583–591. Douglas RS, Kahaly GJ, Ugradar S, et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology. 2022;129:438–449. Belinsky I, Creighton FX Jr, Mahoney N, et al. Teprotumumab and hearing loss: case series and proposal for audiologic monitoring. Ophthalmic Plast Reconstr Surg. 2022;38:73–78. Smith TJ. The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy. Eye (Lond). 2019;33:200–205. Xin Y, Xu F, Gao Y, et al. Pharmacokinetics and exposure-response relationship of teprotumumab, an insulin-like growth factor-1 receptor-blocking antibody, in thyroid eye disease. Clin Pharmacokinet. 2021;60:1029–1040. Kahaly GJ, Douglas RS, Holt RJ, et al. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two andomized, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 2021;9:360–372. Ma H, Zhang T, Shen H, et al. The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy. Br J Clin Pharmacol. 2014;77:917–928. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II sarcoma alliance for research through collaboration study. J Clin Oncol. 2011;29:4541–4547. Kurzrock R, Patnaik A, Aisner J, et al. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res. 2010;16:2458–2465. Ramalingam SS, Spigel DR, Chen D, et al. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol. 2011;29:4574–4580. |
| المشرفين على المادة: | Y64GQ0KC0A (teprotumumab) 0 (Antibodies, Monoclonal, Humanized) 0 (Antibodies, Monoclonal) |
| تواريخ الأحداث: | Date Created: 20230901 Date Completed: 20231106 Latest Revision: 20240207 |
| رمز التحديث: | 20240208 |
| DOI: | 10.1097/IOP.0000000000002482 |
| PMID: | 37656913 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-2677 |
|---|---|
| DOI: | 10.1097/IOP.0000000000002482 |